Navigation Links
Verum.de Exhibits at Outsourcing in Clinical Trials Southern California
Date:8/29/2013

SAN DIEGO, Aug. 29, 2013 /PRNewswire/ -- Verum.de, a full-clinical service, German-based contract research organization (CRO) with seven offices throughout Europe and a U.S. office in Carlsbad, Calif., will participate in the Outsourcing in Clinical Trials Southern California meeting in San Diego, Sept. 24-25, 2013. Verum will exhibit at booth #3 and will answer questions on conducting international clinical trials, logistics of study medication and bio samples (im- and exportation, packaging, distribution and storage) specifically in Central Eastern European (CEE) countries.

(Logo: http://photos.prnewswire.com/prnh/20120807/LA53176LOGO)  

Southern California is the newest location for the OCT series. This meeting brings together life science professionals interested in growth, innovation and latest trends of the industry, focused on topics relevant to pharma, biotech, and medical device companies. Attendees who visit the Verum booth will have the opportunity to meet Christian Sacher, CEO, Dagmar Siebold, European director of client relations, and US and European business development teams.

"We look forward to expanding our attendance in US industry events and to supporting the life sciences sector in Southern California where one of our offices is located," said Kristi Clark, president of Verum's U.S. office and operations. "With San Diego being one of the major hubs for pharma and biotech in the world, this exhibit will give us the opportunity to showcase our expertise to potential clients and partners interested in clinical trial services in CEE."

To set up an appointment or to learn more about Verum.de, contact Chuck Cade, VP, business development, US at cc@verum.us or call +1 (512) 917-8017.

About Verum.de
Verum has been the first Western-standard full-service CRO specializing in CEE/CIS countries, with key competency in full clinical service for Phases II-IV. Verum has successfully completed more than 130 clinical trials with about 40,000 patients for pharma, biotech and medical device companies as well as the US National Institutes of Health (NIH). The company's expertise covers cardiovascular, neurology, psychiatry, pain, oncology, and more. Operating since 1992, Verum is the strongest player in high recruiting CEE areas and maintains offices all over Eastern Europe, Germany and the US. More information can be found at http://www.verum.de.

CONTACT:
Antonia Genov
antonia@clearpointagency.com
760-230-2424


'/>"/>
SOURCE Verum.de
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Verum.de Chosen to Provide Clinical Research Services for Oncology Center in Romania
2. Verified Clinical Trials Exhibits at the Annual 2013 Partnerships In Clinical Trials to Discuss the Professional Research Subject and the Clinical Trial Database Registry
3. Patheon Exhibits and Presents at the 2013 IQPC Global Formulation and Drug Delivery Summit
4. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
5. NanoLogix Announces Development of Multi-Well, Rapid Diagnostic Test Variant and Exhibits at the American Society for Microbiology General Meeting in San Francisco
6. Clinovo Sponsors Outsourcing in Clinical Trials Southern California Conference 2013, in La Jolla (CA), September 24-25
7. Clinical Development, Contracts and Outsourcing in MENA & APAC, New Webinar Hosted by Xtalks
8. Clinovo Sponsors the First Outsourcing in Clinical Trials: Medical Devices & Diagnostics Conference, June 12-13, 2013 in Saint Paul, Minnesota
9. DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks
10. Cyber Infrastructure Pvt. Ltd. (CIS) Begins Offering BOT (Build-Operate-Transfer) IT-Outsourcing Model for SMEs
11. Global Healthcare Contract Research Outsourcing Market is expected to reach USD 65.03 billion by 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Rolf K. Hoffmann, ... faculty of the University of North Carolina Kenan-Flagler Business School effective ... at UNC Kenan-Flagler, with a focus on the school’s international efforts, leading classes ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:5/20/2016)... 2016  VoiceIt is excited to announce its ... By working together, VoiceIt and VoicePass will ... VoicePass take slightly different approaches to voice biometrics, ... and usability. ... partnership. "This marketing and technology partnership ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):